monohydrochloride) is a novel tropanemethanamine benzodioxane derivative that possesses high and selective affinities for D2-like and 5-HT 1A receptors (K I ¼ 0.8, 0.2, and 0.2 nM for human D 2 , D 3 , and 5-HT 1A , respectively). In vivo, SSR181507 inhibited [ 3 H]raclopride binding to D 2 receptors in the rat (ID 50 ¼ 0.9 and 1 mg/kg, i.p. in limbic system and striatum, respectively). It displayed D 2 antagonist and 5-HT 1A agonist properties in the same concentration range in vitro (IC 50 ¼ 5.3 nM and EC 50 ¼ 2.3 nM, respectively, in the GTPgS model) and in the same dose range in vivo (ED 50 ¼ 1.6 and 0.7 mg/kg, i.p. on striatal DA and 5-HT synthesis, respectively, and 0.03-0.3 mg/kg, i.v. on dorsal raphe nucleus firing rate). It selectively enhanced Fos immunoreactivity in mesocorticolimbic areas as compared to the striatum. This regional selectivity was confirmed in electrophysiological studies where SSR181507, given acutely (0.1-3 mg/kg, i.p.) or chronically (3 mg/kg, i.p., o.d., 22 days), increased or decreased, respectively, the number of spontaneous active DA cells in the ventral tegmental area, but not in the substantia nigra. Moreover, SSR181507 increased both basal and phasic DA efflux (as assessed by microdialysis and electrochemistry) in the medial prefrontal cortex and nucleus accumbens, but not in the striatum. This study shows that the combination of D 2 receptor antagonism and 5-HT 1A agonism, in the same dose range, confers on SSR181507 a unique neurochemical and electrophysiological profile and suggests the potential of this compound for the treatment of the main dimensions of schizophrenia.
INTRODUCTION
Schizophrenia is a devastating psychiatric disorder characterized by a diversity of symptoms: the so-called positive symptoms (such as delusions and hallucinations), negative symptoms (such as blunted affect and social withdrawal), as well as cognitive-attentional deficits. While classical antipsychotics do show efficacy against the positive symptoms of schizophrenia, negative symptoms and cognitive defects are clearly less responsive to therapeutic intervention. The main limit to their clinical use, however, resides in their side effects, such as extrapyramidal signs (EPS), neuroendocrine disturbances, sexual dysfunction, orthostatic hypotension, weight gain, and excessive sedation. A second generation of antipsychotics, commonly referred to as 'atypical antipsychotics', is characterized by a modest progress in effect on positive symptoms of schizophrenia, but by an improved separation of efficacy against the positive symptoms and the induction of EPS, and by some efficiency on the cognitive symptoms of schizophrenia (Meltzer and McGurk, 1999) . Conceptually, their putative mechanisms are related to a limbic selectivity characterized by a selective blockade of limbic dopaminergic neurotransmission. The predominant profile of these atypical antipsychotics appears to be blockade of both 5-HT 2A and DA D 2 receptors (multireceptor concept). Indeed, although activity at 5-HT 2A receptors is not essential for antipsychotic efficacy, it has been proposed that the atypical clinical profile of several antipsychotics could be related to their ratio of affinities for 5-HT 2A and DA D 2 receptors (Meltzer, 1999; Scatton and Sanger, 2000) . Some of them also interact with additional receptors such as a-adrenergic receptor subtypes, histamine H 1 , or muscarinic receptors (Miyamoto et al, 2000) . The multiplicity of pharmacological targets for these atypical antipsychotics not only fuels the debate about the therapeutically relevant mechanism for such drugs, but also leads to a side-effect profile, besides EPS, that remains open for improvement. That highly selective DA D 2 and D 3 receptor blockade is sufficient to reveal limbic selectivity is demonstrated by amisulpride, which shows atypical antipsychotic activity and also an improved efficacy against the primary negative symptoms of schizophrenia (Boyer et al, 1995) .
Although atypical antipsychotics have been a major advance in the treatment of schizophrenia, there is still a need for improvement, as a significant proportion of patients remain refractory to treatment, and negative and cognitive symptoms are little improved by current treatment. Recent preclinical and clinical data have suggested that combining antagonist activity at DA D 2 receptors with agonist activity at 5-HT 1A receptors might offer a promising alternative to schizophrenia treatment (see Meltzer and McGurk, 1999; Millan, 2000; Ichikawa et al, 2001; Bantick et al, 2001 for reviews) .
Autoradiographic studies in post-mortem schizophrenic patients have shown that 5-HT 1A binding site densities are increased in the dorsolateral prefrontal cortex and orbital frontal cortex (Burnet et al, 1996; Simpson et al, 1996) and PET studies recently revealed an increase in cortical 5-HT 1A receptor binding in schizophrenia (Kasper et al, 2002) , thus suggesting that the 5-HT 1A receptor may indeed be implicated in this disease or its manifestations. Furthermore, 5-HT 1A agonists attenuate certain DA D 2 receptormediated motor side effects: 8-OH-DPAT and ipsapirone, two prototypical 5-HT 1A receptor agonists, prevent or reduce haloperidol-induced catalepsy in rodents (Wadenberg and Ahlenius, 1991) . In clinical studies, signs of Parkinsonism were improved by the addition of buspirone (Goff et al, 1991) to neuroleptic-treated schizophrenic patients. Thus, DA D 2 receptor antagonists with high affinity and agonist properties at the 5-HT 1A receptor should have a low incidence of EPS. Moreover, recent work with tandospirone (Sumiyoshi et al, 2000 (Sumiyoshi et al, , 2001 have suggested the usefulness of 5-HT 1A agonists for improving cognition in patients with schizophrenia. It has also been proposed that the ability of atypical antipsychotics to alleviate the negative and cognitive symptoms of schizophrenia is related to the fact that they enhance DA release in the medial prefrontal cortex (Kapur and Remington, 1996) . As selective 5-HT 1A agonists increase DA release in this structure (Arborelius et al, 1993) , this property may lead to efficacy against the negative-cognitive symptomatology in schizophrenia. Finally, since stress and anxiety are often associated with schizophrenic episodes (Liberman and Corrigan, 1992) and because up to 75% of first diagnosed schizophrenics are depressed (Koreen et al, 1993) , relief of these symptoms is also a desirable property. Along with anxiolysis (Borison et al, 1990) , antidepressant activity has also been associated with 5-HT 1A agonism (Robinson et al, 1989) , thus suggesting that compounds with this activity should have additional advantages on schizophreniaassociated mood disorders.
We have recently synthesized a compound, SSR181507 (Figure 1 ), which combines DA D 2 antagonism and 5-HT 1A agonism in the same concentration and dose range. In the present study, we report on the binding profile of this compound and its intrinsic and functional activity at these two receptors, on its electrophysiological (firing of serotonergic cell bodies of dorsal raphe nucleus (DRN), number of active cells in DA cell bodies) and neurochemical (Fos expression, basal and evoked DA efflux) profile in support of the above-mentioned hypothesis. A companion paper (Depoortere et al, 2003) provides further psychopharmacological evidence to this end.
MATERIALS AND METHODS

Animals
Unless otherwise indicated, adult male Sprague-Dawley rats (OFA from Iffa Credo, Les Oncins, France or COBS from Charles River, St Aubin-les-Elbeuf, France) and Dunkin Hartley guinea-pigs (Iffa Credo) were used. All experiments were performed in accordance with the 'Guide and Care and Use of Laboratory Animals' (National Institutes of Health) and were approved by the in-house Animal Ethics Committee. WAY100635, amisulpride, clozapine, olanzapine, haloperidol, eliprodil, paroxetine, NAN-190 , and 8-OH-DPAT were synthesized by the Chemistry Department of Sanofi-Synthelabo Recherche. Other chemicals (apomorphine, pargyline) were obtained commercially at the highest purity available.
Material and Drugs
Drugs were administered by the i.p. route, except when indicated otherwise; control groups received an equal volume of the corresponding vehicle. Doses refer to the free base equivalent. Pargyline, clozapine, and haloperidol were dissolved in saline (0.9% NaCl). SSR181507 and WAY100635 were suspended with Tween 80 (0.1%) in saline vehicle. Sanger and Schoemaker, 1992; Schoemaker and Langer, 1986) . Assay conditions and references for competition binding studies at human receptor subtypes are summarized in Table 2 . Results were evaluated as the drug concentration required to inhibit 50% of specific radioligand binding and converted to K I values as described by Cheng and Prusoff (1973) .
Radioligand Binding Studies In Vivo ]raclopride selectively recognizes DA D2-like receptors in vitro and was used to label these receptors in vivo (Köhler et al, 1985 (Furchgott, 1972) .
Measurement of Dopamine and Serotonin Synthesis Rates
The rate of DA and serotonin (5-HT) synthesis was estimated by measuring the accumulation of dihydroxyphenylalanine (L-DOPA) and 5-hydroxytryptophane (5-HTP), respectively, after administration of 100 mg/kg, i.p. of the aromatic L-amino acid decarboxylase inhibitor NSD-1015 (Schoemaker et al, 1997) . At 1 h after administration of SSR181507 (0.3-10 mg/kg, i.p.) and 30 min after the administration of NSD-1015, rats were killed by decapitation and different brain structures (striatum, hippocampus, limbic system (nucleus accumbens, septum, and olfactory tubercle), cortex) were dissected on ice. Brain structures were then weighed, homogenized in 20 volumes of 0.1 N HClO 4 and centrifuged at 10 000 g for 10 min. L-DOPA and 5-HTP levels were measured in the supernatant by HPLC with electrochemical detection as described previously (Schoemaker et al, 1997) .
Identical procedures were used in rats chronically treated with SSR181507 (3 or 10 mg/kg, i.p, b.i.d. for 20 days). In this case, SSR181507 was administered acutely at the dose of 3 mg/kg, i.p., 72 h after the last injection of the repeated treatment of vehicle control or SSR181507.
In Vivo Recording of Dorsal Raphe Neuronal Firing
Rats were anesthetized with chloral hydrate (400 mg/kg, i.p.) and were mounted in a stereotaxic frame after femoral vein cannulation. Additional doses of chloral hydrate were administered to maintain surgical anesthesia throughout the experiment. A burr hole was drilled into the skull over the DRN and tungsten electrodes were lowered (0.5-1 mm anterior to lambda, on the midline, 4.5-5.5 mm under the cortical surface, according to the atlas of Paxinos and Watson (1998) ) for recording spontaneous cell unit activity. Action potentials were amplified and counted by 10-s periods with a spike discriminator connected to a computer driven by the software (Haigler and Aghajanian, 1974 In Vivo Recording of the Number of Spontaneously Active DA Cells Rats were anesthetized with chloral hydrate (400 mg/kg, i.p.) and were mounted in a stereotaxic frame after cannulation of the lateral vein of the tail in order to allow both the i.v. injection of drugs and the continuous infusion of chloral hydrate (120 mg/kg/h). A burr hole was drilled into the skull above the area to be recorded. The micropipettes (glass tubing of 1.5 mm outer diameter that was heated, pulled, and broken under microscopic control to obtain a tip of 2.5 mm diameter) were filled with 0.9% saline and stereotaxically aimed at the vicinity of DA cells in the substantia nigra (SN: A9) or the ventral tegmental area (VTA: A10). The spikes recorded from the micropipette were amplified, filtered (0.1-2 kHz), and visualized on an oscilloscope.
In all, 12 electrode tracks were defined on a 12-box, 240 000 mm 2 grid within the A9 or A10 area, according to the following coordinates: A9 (5.8-5.2 mm anterior to bregma, 1.8-2.2 mm lateral to bregma, 6.5-8.0 mm under the cortical surface), A10 (6.0-5.4 mm anterior to bregma, 0.4-0.8 mm lateral to bregma, 7.0-8.5 mm under the cortical surface). The number of spontaneously active DA cells was counted for each track until the grid was completed. The DA cells were identified and the number of spontaneously firing neurons per electrode track was determined according to Grace and Bunney (1983) . The effects of SSR181507 on population response were investigated in an acute and a repeated treatment procedure (3 mg/kg, i.p. once daily for a period of 22 days). On the day of the experiment, SSR181507 or vehicle was administered 45-60 min before initiation of the first electrode track. WAY100635 (0.1 mg/ kg, i.v) or apomorphine (0.063 mg/kg, i.v.) was administered after completion of the last electrode track, and cell counting was restarted for an additional five tracks, according to White and Wang (1983) .
In Vivo Measurement of Basal Dopamine Efflux
Basal DA efflux was monitored in the medial prefrontal cortex, nucleus accumbens, or striatum by microdialysis. Adult male Sprague-Dawley rats were anesthetized with chloral hydrate (400 mg/kg, i.p.) and guide cannulae were stereotaxically implanted onto the dura mater above the medial prefrontal cortex (3.2 mm anterior to bregma, 0.6 mm lateral to bregma), the nucleus accumbens (1.7 mm anterior to bregma, 1.0 mm lateral to bregma), and the striatum (0.7 mm anterior to bregma, 3.0 mm lateral to bregma) (Paxinos and Watson, 1998) . At least 5 days after surgery, microdialysis probes (Carnegie Medicine, Stockholm, Sweden), 250 mm in diameter with an exposed membrane length of 3 mm (medial prefrontal cortex) and 2 mm (nucleus accumbens and striatum), were positioned within the guide cannulae (vertical coordinates: 4.5, 8.0, and 8.0 mm, respectively, under the cortical surface) and perfused with artificial cerebrospinal fluid (mM: NaCl, 147; KCl, 4; CaCl 2 , 1.2; MgCl 2 , 1.0) using a CMA/100 pump (Carnegie Medicine) at a flow rate of 2 ml/min. Dialysate samples were collected every 20 min and analyzed using HPLC with electrochemical detection. The average concentration of five stable fractions immediately preceding drug administration was defined as the 100% control value. The area under the curve was expressed relative to these values and was calculated for 120 min after drug administration.
In Vivo Measurement of Evoked Catecholamine Efflux
Rats were anesthetized with urethane (1.15-1.4 g/kg, i.p.), treated with pargyline (75 mg/kg, s.c.), and placed in a stereotaxic frame. Evoked catecholamine (CA) efflux was monitored in the nucleus accumbens or medial prefrontal cortex by electrochemically treated carbon fiber electrodes combined with differential pulse amperometry (DPA). The sensitivity of the treated electrode for CA vs metabolites (o10 vs 100 nM) and the use of pargyline to prevent CA catabolism allow a selective measurement of DA levels in the nucleus accumbens (Suaud-Chagny et al, 1992) . In the medial prefrontal cortex, DA is probably the main source of the CA signal variations induced by the electrical stimulation of the dopaminergic pathway, although a participation of noradrenaline to the evoked CA efflux measured in the medial prefrontal cortex cannot be excluded.
Carbon fiber electrodes (250 mm long and 8 mm in diameter) were electrochemically treated in phosphatebuffered saline (PBS) as previously described (Brun et al, 1995) . Electrodes were then implanted in the nucleus accumbens or the medial prefrontal cortex at the following coordinates: 2.0-2.2 mm anterior to bregma, 1.3 mm lateral to bregma and from 6.5 to 7.0 mm below the cortical surface and 2.7-3.0 mm anterior to bregma, 0.5-0.7 mm lateral to bregma and from 4.0 to 4.5 mm below the cortical surface, respectively (Paxinos and Watson, 1998) . They were connected to a voltammetric recorder (Biopulse; Radiometer Analytical, France). Electrically evoked changes in CA efflux were monitored every second using DPA with the final potential adjusted at +80 mV vs the Ag/AgCl reference electrode (Suaud-Chagny et al, 1992; Brun et al, 1995) . All results were expressed as percentages of the mean of the three effects recorded before drug injection.
Electrical Stimulation of the Dopaminergic Pathway
Electrical stimulation of the ascending dopaminergic pathway was used to evoke short-lasting increases in the extracellular DA concentration. A bipolar stimulating electrode (SNEX-200, Rhodes Medical Instruments, USA) was positioned in the ascending dopaminergic pathway at the following coordinates: 4.0 mm posterior to bregma and 1.0 mm lateral to bregma. The depth (8.2-8.6 mm below the cortical surface) was adjusted for each experiment so that the response was maximal. Electrical stimulations consisted of square current pulses (300 mA, 0.5 ms) and were applied by an isolated stimulator (DS2, Digitimer, USA) every 10 min and for 10 s at the frequency of 20 Hz (nucleus accumbens) or 40 Hz (medial prefrontal cortex).
Fos Immunochemistry
Experiments were performed as described previously (Alonso et al, 1999) . Briefly, rats were anesthetized with sodium pentobarbital (75 mg/kg, i.p.) and perfused transcardially with saline, followed by 4% paraformaldehyde. Brains were postfixed overnight and 50 mm coronal sections were cut using a vibratome. Immunohistochemistry was performed on free-floating tissue sections according to a standard avidin-biotin-peroxidase procedure using an anti-Fos rabbit polyclonal antibody directed against residues 3-16 of the N-terminal region of the Fos protein (sc-52, Santa Cruz Biotechnologies Inc., CA, USA). Sections were imaged through a Leica DMRX microscope, and the Fos-like immunoreactive signal was quantified with an image analysis system (Samba Technologies, Meylan, France) by counting the number of Fos-positive cells.
Statistical Analyses
Statistical differences between groups were assessed using ANOVA tests, followed by Dunnett's post hoc tests.
In DPA experiments, comparisons between treatments were performed using a one-way ANOVA with repeated measures, followed by a Fisher's PLSD post hoc test.
RESULTS
In Vitro Radioligand-Binding Studies SSR181507 showed high affinity for animal DA D 2 , DA D 3 , and 5-HT 1A receptors (K I ¼ 7.5, 3.6, and 4.5 nM, respectively, Table 1 ). Clozapine had a lower affinity for these receptors. Olanzapine, as well as amisulpride and haloperidol, had almost a similar affinity for DA D 2 and DA D 3 receptors, but in contrast to SSR181507, they were devoid of significant affinity for the 5-HT 1A receptor (Table 1) . SSR181507 displayed high affinity for cloned human (h) DA D 2 , DA D 3 , and 5-HT 1A receptor subtypes (K I ¼ 0.8, 0.2, and 0.2 nM, respectively, Table 2 ). It had no affinity for hDA D 1 and hDA D 5 receptor subtypes and had only a modest affinity for hDA D 4 receptor, h5-HT 2A , h5-HT 2C , h5-HT 6 , and h5-HT 7 receptor subtypes, for ha 1D and ha 2A adrenoceptors, and for all five human muscarinic receptor subtypes (selectivity ratio 460-fold, Table 2 ).
In Vivo Radioligand-Binding Studies
In vivo [
3 H]raclopride-binding studies in rats revealed occupancy of DA D 2 receptors by SSR181507 with similar ID 50 values in the limbic system and in the striatum (0.9 7 0.2 and 1.0 7 0.2 mg/kg, i.p., respectively, Table 3 ). In this test, SSR181507 behaved like haloperidol, which (Figure 2a) . Under the same experimental conditions, haloperidol had an IC 50 ¼ 3.9 7 0.8 nM. 
In Vitro Dopamine Release
The electrically evoked [ 3 H]dopamine release from slices of rat striatum is subject to an inhibitory modulation mediated by DA D2-like terminal autoreceptors as shown by the inhibitory effect of the DA agonist, apomorphine (IC 50 ¼ 23 nM). SSR181507 (30 and 100 nM) produced a rightward shift of the apomorphine dose-response curve with an apparent pA 2 ¼ 7.94 ( Figure 3 ).
In Vivo Dopamine and Serotonin Synthesis SSR181507 (0.3-10 mg/kg, i.p.) dose-dependently increased (322% of controls) the synthesis of DA, as measured by the accumulation of L-DOPA, in rat striatum (ED 50 ¼ 1.6 7 0.1 mg/kg, i.p.). In the same dose range, it decreased the synthesis of 5-HT (maximal effect: 42% of controls at 10 mg/kg, i.p.), as measured by the accumulation of 5-HTP in this same structure (ED 50 ¼ 0.7 7 0.3 mg/kg, i.p., Figure 4) . Likewise, SSR181507 increased DA synthesis in the limbic system (ED 50 ¼ 1.1 7 0.1 mg/kg, i.p.) and decreased 5-HT synthesis in the hippocampus and cortex (ED 50 ¼ 4.1 7 3.1 and 1.1 7 0.6 mg/kg, i.p, respectively). Under the same experimental conditions (results not shown), the 5-HT 1A agonist 8-OH-DPAT (0.3 mg/kg, i.p.) decreased striatal 5-HT synthesis (47% of controls) without modifying DA synthesis (96% of controls) and the selective DA D 2 antagonist amisulpride (100 mg/kg, i.p.) only affected striatal DA synthesis (363% of controls vs 98% of controls for 5-HT synthesis). After repeated treatment (20 days at 3 or 10 mg/kg, i.p., b.i.d., followed by 72 h of withdrawal), SSR181507 (3 mg/kg, i.p.) induced changes in DA and 5-HT synthesis similar to those observed in animals who received vehicle chronically ( Figure 5 ).
Number of Spontaneously Active DA Cells
In the rat, acute administration of SSR181507 (0.1-3 mg/kg, i.p.) increased the number of spontaneously active DA cells Profile of SSR181507, a D 2 antagonist/5-HT 1A agonist Y Claustre et al per track in the A10 area but, up to 10 mg/kg, i.p., failed to affect this parameter in the A9 area. In this latter area, when WAY100635 (0.1 mg/kg, i.v.) was administered with an inactive dose of SSR181507 (3 mg/kg, i.p.), the number of active DA cells was increased (Figure 6a) .
S]-GTPγS bound (%)
Following repeated administration (22 days, 3 mg/kg, i.p., o.d.), SSR181507 decreased the number of spontaneously active DA cells in the A10, but not in the A9 area, as compared to controls. The effect of the drug in the A10 area was reversed by an acute injection of apomorphine (63 mg/ kg, i.v.), thus demonstrating the induction of depolarization block. The involvement of the 5-HT 1A agonist property in this selective regional effect was demonstrated by the fact that the injection of WAY100635 (0.1 mg/kg, i.v.) with an inactive dose of SSR181507 (3 mg/kg/day, i.p.), induced an increase in the number of spontaneously active DA cells in the A9 area (Figure 6b ).
Basal DA Efflux Measured by In Vivo Microdialysis
SSR181507 (3 mg/kg, i.p.) markedly increased extracellular DA levels in the nucleus accumbens (164 7 11% of controls), but was devoid of effect in the striatum (Figure 7a ). At 1 mg/kg, i.p., it also increased extracellular DA levels in the medial prefrontal cortex (153 7 10% of controls, Figure 7b ). Under similar experimental conditions, clozapine (10 mg/kg, i.p.) increased this parameter by 173 7 25 and 164 7 32% of controls in the nucleus accumbens and striatum, respectively (results not shown), and by 188 7 14% of controls in the medial prefrontal cortex (Figure 7b ). ]dopamine release was studied using slices from rat striatum. Slices were initially stimulated in the absence of apomorphine and SSR181507 and 40 min thereafter in their presence. Apparent pA 2 values were determined for each concentration of SSR181507 (30 and 100 nM) according to Furchgott (1972) as detailed in Materials and methods (average pA 2 ¼ 7.94). Data shown are means with SEM of 3-13 replicates for each point on the curves. 
Evoked CA Efflux Measured by In Vivo Electrochemistry
Electrical stimulation of the ascending dopaminergic pathway evoked immediate, reversible, and highly reproducible increases in DA efflux in the nucleus accumbens and CA efflux in the medial prefrontal cortex (Suaud-Chagny et al, 1992; Brun et al, 1995) . In the nucleus accumbens, haloperidol (50 mg/kg, s.c.) significantly increased the evoked DA efflux to a maximum of 114 7 21% above predrug values (Figure 8a ). Both doses of SSR181507 (1 and 3 mg/kg, i.p.) elicited a large, sustained, and significant increase in the evoked DA efflux (Figure 8a ). This increase was larger with the highest dose of SSR181507 (maximum, 106 7 22 and 444 7 53% above predrug values for the lowest and highest dose of SSR181507, respectively). WAY100635 (1 mg/kg, i.p.) almost completely blocked the response induced by SSR181507 (3 mg/kg, i.p., Figure 8a ). In the medial prefrontal cortex, haloperidol (50 mg/kg, s.c.) and clozapine (10 mg/kg, s.c.) did not significantly modify the evoked CA efflux (Figure 8b ). In contrast, both doses of SSR181507 (1 and 3 mg/kg, i.p.) elicited a significant increase in the evoked CA efflux (Figure 8b) . Moreover, as observed in the nucleus accumbens, post hoc comparison indicated a significant difference (po0.05) between both doses of SSR181507 in the medial prefrontal cortex (Figure 8b ).
In Vivo Recording of Dorsal Raphe Neuronal Firing
5-HT neurons present a slow (0.5-3 Hz) and regular firing rate and long-duration (0.8-2 ms) biphasic action potentials. SSR181507 induced a marked and dose-dependent inhibition of the neuronal firing rate in the rat DRN (0.03-0.3 mg/kg, i.v., Figure 9a ). Treatment with WAY100635 (0.1 mg/kg, i.v.) reversed the SSR180507-induced inhibition of raphe neurons (Figure 9b ). When administered alone, WAY100635 (0.1 mg/kg, i.v.) had no effect (not shown).
Fos Immunoreactivity
In the rat, SSR181507 (1-10 mg/kg, i.p.), like clozapine (20 mg/kg, i.p.), selectively increased the number of Fospositive cells in mesocorticolimbic areas (prefrontal cortex, nucleus accumbens shell, dorsomedial caudate putamen Profile of SSR181507, a D 2 antagonist/5-HT 1A agonist Y Claustre et al (CPu)) and did not alter or weakly affected this parameter in motor-related structures (nucleus accumbens core, dorsolateral CPu) (Figure 10 ). In contrast, haloperidol (0.5 mg/kg, i.p.) increased the number of Fos-positive cells to a similar extent in all these limbic and motor-related brain regions and failed to affect this parameter in the prefrontal cortex (Figure 10 ).
DISCUSSION
We took advantage of the discovery of SSR181507 to test whether the combination in the same molecule of selective DA D 2 receptor antagonism and 5-HT 1A agonist activity would result in a pharmacological and neurochemical profile characteristic of atypical antipsychotics. The present report and its companion paper dealing with the psychopharmacological profile of SSR181507 (Depoortere et al, 2003) provide strong evidence that this dual mechanism of action results in a drug profile compatible with an original, atypical antipsychotic activity.
Selectivity for DA D 2 and 5-HT 1A receptors SSR181507 has a similar and high-nanomolar affinity for DA D 2 and D 3 receptors in vitro. It does not bind to DA D 1 and DA D 5 subtypes and in contrast to almost all atypical antipsychotics (clozapine, risperidone, olanzapine, ziprasidone), it has no appreciable affinity for the DA D 4 subtype (Miyamoto et al, 2000) .
It also has a high affinity and selectivity for the 5-HT 1A receptor subtype. Some atypical antipsychotics such as ziprasidone, iloperidone, and aripiprazole also display significant affinity for 5-HT 1A receptor but in contrast to SSR181507, they also bind to other 5-HT receptor subtypes, Profile of SSR181507, a D 2 antagonist/5-HT 1A agonist Y Claustre et al for example, the 5-HT 2A subtype (Richelson and Souder, 2000; Jordan et al, 2002) . SSR181507 also has no noticeable affinity for a-adrenergic, muscarinic M 1 , and histamine H 1 receptors (that are thought to be involved in the autonomic and sedative side effects of antipsychotics).
Thus, in vitro, SSR181507 shows a unique profile in the sense that it selectively binds to the DA D 2 and 5-HT 1A receptor subtypes with similar nanomolar affinity.
Our findings in vivo confirmed this binding profile. Thus, SSR181507 inhibits the in vivo binding of Intrinsic Activity at DA D 2 and 5-HT 1A Receptors
The functional activity of SSR181507 at DA D 2 and 5-HT 1A receptors was evaluated in the [
35 S]GTPgS-binding model. In this in vitro model, SSR181507 behaved as a potent antagonist at the DA D 2 receptor and had the profile of a full agonist or of a high-efficacy partial agonist at the 5-HT 1A receptor. In contrast, ziprasidone, clozapine, and aripiprazole behave as partial agonists at cloned 5-HT 1A receptors (Newman-Tancredi et al, 1998; Jordan et al, 2002) . SSR181507 also antagonized rat presynaptic DA D 2 receptors, as demonstrated by the rightward shift by this drug of the concentration-response curve of DA agonistinduced decrease of [ 3 H]dopamine release in rat striatal slices.
That SSR181507 blocks rat DA D 2 receptors in vivo was suggested by the fact that this drug increased striatal and limbic DA synthesis. As would be expected for a 5-HT 1A agonist, SSR181507, in the same dose range, inhibited the synthesis of 5-HT in several rat brain areas, and its maximal effect was similar to that of 8-OH-DPAT, thus confirming that it behaves as a full 5-HT 1A agonist on the serotonergic transmission. Electrophysiological data showing that SSR181507 decreased the firing rate of 5-HT neurons in the dorsal raphe are also compatible with activation of 5-HT 1A receptors by this drug. This effect is mediated by selective activation of 5-HT 1A receptors as revealed by its sensitivity to the 5-HT 1A antagonist WAY100635. In this model, the total inhibition of firing rate at the dose of 0.3 mg/kg, i.v. is also in agreement with a full 5-HT 1A agonist profile. However, it is known that the intrinsic activity is dependent on the experimental model. In the in vitro GTPgS model, it is highly dependent on the density of recombinant 5-HT 1A receptors and in the two preceding in vivo models, it reflects the activity at presynaptic 5-HT 1A receptors (Newman-Tancredi et al, 1998) . Interestingly, in an integrated functional model in rats involving 5-HT 1A postsynaptic receptors (serotonergic syndrome), SSR181507 has the profile of a partial 5-HT 1A agonist (Depoortere et al, 2003) . The effects of SSR181507 on DA and 5-HT synthesis were of long duration (at least 6 h, results not shown) and persisted after repeated treatment for 20 days, demonstrating that there is no development of tolerance.
Mesocorticolimbic Selectivity and Atypical Antipsychotic Profile
The combination of DA D 2 receptor antagonism and 5-HT 1A agonist effect was expected to confer on SSR181507 selectivity for mesocortical and mesolimbic dopaminergic activity, resulting in a pharmacological profile compatible with atypical antipsychotic properties (see Introduction).
Electrophysiological studies confirmed the limbic selectivity of SSR181507. Thus, acute treatment with SSR181507 resulted in an increased number of spontaneously active DA neurons in the VTA, but not in the SN. Repeated treatment with SSR181507 reduced the number of spontaneously active DA neurons in the VTA without modifying it in the SN. In this latter model, SSR181507 behaved like olanzapine, sertindole, and risperidone, which decrease the number of spontaneously active DA cells in the mesolimbic system only, but differed from quetiapine and ziprasidone Profile of SSR181507, a D 2 antagonist/5-HT 1A agonist Y Claustre et al that also affect the nigrostriatal system (Skarsfeldt, 1995) . This model of depolarization inactivation of DA neurons is generally considered to be of predictive value of the nature of antipsychotic compounds (Jones-Humble et al, 1996) . The regional selectivity of SSR181507 could be due to its agonist activity at 5-HT 1A receptors. Indeed, the capacity of SSR181507 to affect selectively the number of spontaneously active DA cells in the VTA disappeared in the presence of WAY100635. Moreover, the fact that this limbic selectivity was still present after a chronic treatment with SSR181507 confirms the lack of desensitization of 5-HT 1A receptors.
The regional effect of antipsychotics on DA release has also been shown to highlight their typical or atypical profile (Nomikos et al, 1994; Volonté et al, 1997) . The effect of SSR181507 on basal and evoked DA efflux in rat brain areas also supports the mesocorticolimbic selectivity of this compound. Thus, SSR181507 enhanced basal DA efflux in the nucleus accumbens and medial prefrontal cortex, but not in the striatum. A similar regional selectivity was previously found for the atypical antipsychotics ziprasidone, clozapine, olanzapine, and risperidone, while haloperidol increased DA efflux more markedly in the striatum than in the nucleus accumbens, and was inactive in the prefrontal cortex (Kuroki et al, 1999; Rollema et al, 2000) . The limbic selectivity of SSR181507 is likely related to 5-HT 1A receptor activation, as its cortical response is antagonized (results not shown) by a 5-HT 1A antagonist (SL88.0338-08). Moreover 5-HT 1A agonists are known to increase cortical DA efflux without affecting striatal DA efflux (Arborelius et al, 1993; Rollema et al, 2000) . Ichikawa et al (2001) recently hypothesized that simultaneous blockade of 5-HT 2A and DA D 2 receptors causes an increase in cortical DA efflux by facilitating 5-HT 1A agonist activity by endogenous 5-HT. It may thus be suggested that, by directly activating 5-HT 1A receptors, SSR181507 is functionally equivalent to atypical antipsychotics that indirectly achieve this effect.
The 5-HT 1A agonist activity of SSR181507 may also account for its original neurochemical profile on evoked DA efflux, as its effect in the nucleus accumbens was antagonized by WAY100635. In the medial prefrontal cortex, in contrast to clozapine and haloperidol, SSR181507 dose-dependently increased evoked CA efflux. The site(s) at which 5-HT 1A receptors control DA neuron activity is still a matter of debate. A direct effect on DA cell bodies seems to be excluded as neither 5-HT 1A receptor protein nor mRNA have been detected in the VTA and SN (Miquel et al, 1991) . Moreover, since DA efflux was evoked by electrical stimulation of the ascending dopaminergic pathway, activation of 5-HT 1A autoreceptors present on DRN neurons afferent to the VTA cannot be invoked. As suggested by Sakaue et al (2000) , 5-HT/DA interactions could take place directly in the medial prefrontal cortex, via the activation of 5-HT 1A receptors located on postsynaptic neurons.
A disruption in the function of the prefrontal cortex ('hypofrontality') is thought to play a major role in the negative symptoms and cognitive deficit of schizophrenia. The robust increase in basal and evoked DA output in the medial prefrontal cortex induced by SSR181507 suggests that this drug may improve negative symptoms (Weinberger and Lipska, 1995) and also cognitive-attentional symptoms of the pathology (Meltzer and McGurk, 1999) .
We have shown that SSR181507 has a high affinity for the DA D 3 receptor subtype. However, complementary experiments have revealed that SSR181507 behaves as a partial agonist at this receptor (result not shown), thus suggesting that its antipsychotic profile can hardly be explained by an interaction with this receptor. Moreover, disappointing results regarding the behavioral phenotype of DA D 3 receptor knockout mice, and the lack of consistency in the behavioral effects of the different putative DA D 3 receptor ligands, have cast some doubt about the in vivo function of this receptor, and one step beyond, about its possible relevance in schizophrenia (Depoortere et al, 2002) .
The immunochemistry of the Fos protein has been shown to be useful in mapping functional pathways in the central nervous system and especially in identifying brain areas that are targets for antipsychotics. Moreover, the ability of these drugs to increase Fos protein expression in the striatal complex has been considered useful in discriminating between typical and atypical antipsychotic compounds (Deutch et al, 1992; Robertson and Fibiger, 1992) . In contrast to haloperidol, but like most atypical antipsychotics, SSR181507 did not affect Fos immunoreactivity in the regions implicated in the control of extrapyramidal motor function. However, like clozapine, it markedly enhanced the expression of Fos protein in mesocorticolimbic regions that are involved in the control of affective and motivational behaviors. In this respect, SSR181507 clearly behaves as an atypical antipsychotic. It is noticeable, however, that among atypical antipsychotics that similarly increase Fos expression in limbic areas, only some of them also enhance this expression in the medial prefrontal cortex (Deutch et al, 1992; Semba et al, 1996) . Interestingly, it has been shown (Tremblay et al, 1998 ) that the 5-HT 1A agonist 8-OH-DPAT is able to convert the 'typical' pattern of haloperidol on c-fos expression into a pattern resembling that of clozapine, suggesting that the original profile of Fos protein expression of SSR181507 may be due to its dual 5-HT 1A agonist and DA D 2 antagonist properties.
CONCLUSION
SSR181507 has a unique neurochemical and electrophysiological profile that is linked to its dual properties (DA D 2 antagonist and 5-HT 1A agonist) expressed in the same dose range. Several advantages may be expected from such a profile and SSR181507 should have the features of an atypical antipsychotic compound. It should have efficacy against positive, and also negative and cognitive symptoms of schizophrenia and should lack the liability of extrapyramidal and other significant side effects. In addition, it should be efficacious on schizophrenia-associated mood and anxiety disorders. A companion paper dealing with the psychopharmacological profile of SSR181507 (Depoortere et al, 2003) adds further weight to these hypotheses.
